Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 16/20 | 0.61 |
| ▸ | GRK5 | P34947 | 1/20 | 0.56 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.46 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.42 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2949835 | 0.81 | FYN (0.57) | FYN | |
| SCHEMBL2945294 | 0.81 | FYN (0.38) | FYNGRK5MITFALDH1A1PKM | |
| SCHEMBL2943519 | 0.80 | FYN (0.55) | FYNCAMK2DMITFALDH1A1PKM | |
| SCHEMBL2947648 | 0.79 | FYN (0.61) | FYNGRK5LRRK2 | |
| SCHEMBL2949657 | 0.77 | SMN1; SMN2 (0.42) | FYNMITFALDH1A1PKMSMN1; SMN2 | |
| SCHEMBL2944043 | 0.77 | FYN (0.57) | FYNGRK5LRRK2MITFALDH1A1 | |
| SCHEMBL2943238 | 0.77 | FYN (0.59) | FYN | |
| SCHEMBL18613329 | 0.76 | FYN (1.00) | FYNGRK5LRRK2CAMK2D | |
| SCHEMBL2947183 | 0.76 | FYN (0.61) | FYN | |
| SCHEMBL2941584 | 0.76 | FYN (0.56) | FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750000-B2 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER SCHERING PHARMA AG (DE) | 2010-07-06 | — | — | US | disclosed |
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | MAP4K2, MAP3K1, MAP3K2 | FYN 421/4885GRK5 212/4885LRRK2 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.